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Minocycline as A Substitute for Doxycycline in
Targeted Scenarios: A Systematic Review
Nicholas W. Carris,1,2 Joe Pardo,4 Jose Montero,3 and Kristy M. Shaeer1,3
1

Department of Pharmacotherapeutics and Clinical Research, University of South Florida College of Pharmacy, Departments of 2Family Medicine, 3Internal
Medicine, University of South Florida, Morsani College of Medicine, Tampa; and 4Department of Pharmacy, North Florida/South Georgia Veterans Health
System, Gainesville

Doxycycline, a commonly prescribed tetracycline, remains on intermittent shortage. We systematically reviewed
the literature to assess minocycline as an alternative to doxycycline in select conditions, given doxycycline’s continued shortage. We identiﬁed 19 studies, 10 of which were published before 2000. Thirteen of the studies were
prospective, but only 1 of these studies was randomized. Based on the available data, we found minocycline to be
a reasonable substitute for doxycycline in the following scenarios: skin and soft-tissue infections and outpatient
treatment of community-acquired pneumonia in young, otherwise healthy patients or in patients with macrolide-resistant Mycoplasma pneumoniae, as well as Lyme disease prophylaxis and select rickettsial disease should
doxycycline be unavailable.
Keywords. alternatives; doxycycline; minocycline; shortage; substitution.

Antibacterial drug shortages are a growing interference
in the clinical management of infectious diseases [1–4].
Close to 150 antibacterial agents experienced shortages
between 2001 and 2013, with nearly one quarter of
these drugs experiencing more than 1 shortage [2].
The impact of a drug shortage is felt at the patientphysician interface and on the institutional level.
Seventy-eight percent of infectious diseases physicians
surveyed reported that antimicrobial shortages have
had a negative impact on their practice [5]. Furthermore, the difﬁculty of drug procurement during a
shortage is often compounded by a substantial price increase for the products that remain on the market.
Members of the US Congress have deliberated over
how to assure the availability of clinically important
generic drugs in the setting of shortage-driven market manipulations [4]. A centerpiece of congressional
discussions was the example of oral doxycycline. Doxycycline, a tetracycline antibiotic with myriad labeled
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indications, experienced a 2000% increase in average retail price between 2012 and 2013 [6], and currently the
list price for doxycycline is as high as $19 per capsule in
our network. In the face of an inconsistent and steeply
priced doxycycline supply, institutions have been forced
to consider alternate therapies. Minocycline has
emerged as a candidate to bridge therapeutic gaps and
conserve ﬁnancial resources, potentially serving as a
simple substitute across a broad range of indications.
The objective of this review was to summarize available
study evidence and identify a clinical role for minocycline in light of the current or future shortages of
doxycycline.

TETRACYCLINE OVERVIEW
Pharmacology and Pharmacokinetics

Tetracycline antibiotics exert their antibacterial action
by disruption of protein synthesis. This is accomplished
through reversible binding to the 30S subunit of the
bacterial ribosome, which interferes with the interaction
between aminoacyl transfer-RNA and messenger RNA
[7, 8]. Doxycycline and minocycline are both secondgeneration tetracyclines with similar chemical structures (Figure 1) [7–9]. Minocycline is distinguished by
minor structural differences at carbons 5 and 6 and the
addition of a dimethylamino group at position 7 [8, 10].
Systematic Review of Minocycline
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Molecular structures of doxycycline and minocycline [7, 9].

These structural differences enhance the lipophilicity of minocycline compared with other tetracycline antibiotics. Both
agents are between 90% and 100% bioavailable when taken orally, although absorption is impaired when coadministered with
divalent and trivalent cations. Approximately 30%–65% of
doxycycline is renally eliminated, with the remaining excretion
occurring in the feces and bile [11–14]. In contrast, minocycline undergoes hepatic biotransformation. Metabolites and
unchanged drug are eliminated in the urine and feces, with
only 10% of the parent compound recovered unchanged in
the urine.
Adverse Drug Reactions

The most common adverse drug reactions (ADRs) are characteristic of the tetracycline class: gastrointestinal disturbances,
esophagitis, photosensitivity, pediatric tooth discoloration,
and, rarely, hepatotoxicity, hypersensitivity, and idiopathic intracranial hypertension. Minocycline is more likely to cause
other central nervous system effects (eg, dizziness, lack of concentration, ataxia, vertigo, tinnitus associated with weakness,
nausea, and vomiting) and pigmentation of various body sites
[8]. Overall, ADRs are reported more frequently for minocycline, but both drugs are generally well tolerated. The comparative safety of doxycycline and minocycline has been reviewed
in detail previously [15].
Spectrum of Activity

Doxycycline and minocycline have comparable in vitro activity.
Their antibacterial spectrum encompasses commonly isolated
Gram-positive and Gram-negative bacteria (eg, staphylococci,
streptococci, certain Enterobacteriaceae). In addition, activity
is noted against atypical pathogens involved in pulmonary
and sexually transmitted infections, Rickettsia, and the infectious agents of other less common syndromes (eg, brucellosis,
melioidosis, leptospirosis, anthrax, plague, and Q fever).
Minocycline has emerged as the tetracycline of choice for multidrug-resistant Acinetobacter baumannii infections, although
doxycycline has also demonstrated activity. The use of tetracyclines for A baumannii infections was recently reviewed [16].
2
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Clinical Efﬁcacy

The clinical efﬁcacy of minocycline should be critically evaluated before recommending direct therapeutic substitution
for doxycycline. To our knowledge, this review is the ﬁrst of
its kind assessing the potential for minocycline use or substitution for doxycycline in targeted clinical scenarios. Because
doxycycline can be used in the treatment of more than 30 different conditions and infections, we elected to review clinical
data regarding minocycline in 4 speciﬁc scenarios, which were
chosen a priori [9]. Skin and soft-tissue infections (SSTIs) and
community-acquired pneumonia (CAP) were chosen for review because they are 2 of the most common infections that
can be treated with tetracyclines [17, 18]. Lyme disease prophylaxis and the treatment of rickettsial disease were chosen
for review because there is a limitation in the guidance previously provided by the Centers for Disease Control and Prevention (CDC) should doxycycline be entirely unavailable [1].

METHODS
Search Strategy and Selection Criteria

We searched Medline through PubMed and EMBASE via Ovid
(up to August 20, 2015) for publications in English related to
minocycline’s use in SSTIs, CAP, tickborne rickettsial disease,
and Lyme disease. We included publications if they reported
original data from prospective clinical trials, prospective cohorts, or retrospective cohorts or cases series with ≥10 patients.
We required clinical outcomes to be reported. The speciﬁc
search terms we used were as follows: (minocycline [MeSH
Terms] OR minocycline [Text Word]) AND ( pneumonia
[Text Word] OR pneumonia [MeSH Terms] OR soft tissue infection [MeSH Terms] OR soft tissue infection [Text Word] OR
Rickettsia [Text Word] OR Rickettsia [MeSH Terms] OR Rocky
Mountain Spotted Fever [Text Word] OR Rocky Mountain
Spotted Fever [MeSH Terms] OR Erlichiosis [Text Word] OR
Erlichiosis [MeSH Terms] OR Anaplasmosis [Text Word] OR
Anaplasmosis [MeSH Terms] OR Lyme Disease [Text word]
OR Lyme Disease [MeSH Terms]). Then, we reviewed the references of reports identiﬁed by this search for additional reports
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Figure 1.

to include. Finally, all investigators critically reviewed and
searched medical literature for additional pertinent reports.
These details represent the full protocol for study identiﬁcation.
Studies for inclusion were identiﬁed by 1 investigator (N.W.C.)
and were conﬁrmed by all coinvestigators. We resolved discrepancies by consensus.
Data Abstraction and Analysis

RESULTS
Literature Review

The electronic search of Medline through PubMed identiﬁed 483
titles. Of the 43 reports [19–61] selected for full review, 23 reports
[38–60] were excluded for reason before abstraction (Figure 2).
One additional title [61] was excluded during record abstraction
because key data were missing regarding the use of minocycline.
The remaining 19 reports [19–37] are described in Table 1. No
additional titles were identiﬁed through EMBASE. We identiﬁed
8 reports related to SSTIs [19–26], 5 related to CAP [26–30], 6
related to Lyme disease [31–36], and 1 related to rickettsial disease [37]. Six of the published reports were retrospective in nature, whereas 13 were prospective. Of the prospective studies,
only 1 was randomized—however open-label—whereas an additional 6 included clinical outcomes on treatments in addition to
minocycline. Published reports were from 1971 to 2013 and included outcome data on 336 patients treated with minocycline.

Community-Acquired Pneumonia

All but 1 identiﬁed report focused on the treatment of Mycoplasma pneumoniae [26]. In addition, these reports were published recently, all from Japan, and primarily related to
macrolide-resistant M pneumoniae [27–30]. All studies were
prospective, although none were randomized. Three of the reports are exclusively related to pediatrics, whereas 1 included
adults [30]. In all studies, the clinical outcome was defervescence, which occurred in a large proportion of patients
(85%–100%). Three studies included treatments other than
minocycline—eg, doxycycline, quinolones, and macrolides—
and in each study, minocycline had the highest proportion of
responders. However, comparisons should be made cautiously
due to the observational nature of these studies. An additional
limitation is that the majority of the studies focused on conﬁrmed M pneumoniae rather than empiric treatment of CAP.
The remaining report included patients with mixed pneumonia
presentations, not exclusively CAP [26]. Although there was
great heterogeneity in patient presentation, all were considered
“severe”. All 14 patients achieved a satisfactory clinical response
after intravenous minocycline therapy.
Lyme Disease Prophylaxis

Skin and Soft Tissue Infections

In 3 of the studies regarding SSTIs, minocycline was dosed with
an initial 200 mg loading dose, and 2 of those studies continued

No reports were identiﬁed that assessed Lyme disease prophylaxis with minocycline. The 6 included studies (all completed in Europe) assessed minocycline in the treatment of early
Systematic Review of Minocycline
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Data were abstracted after study eligibility was determined by the
investigators. Data were abstracted using a standardized table
(Table 1) and were corrected and conﬁrmed by all investigators.
The following information was retrieved: author, year, sample
size, study design/setting, population, treatment, outcomes, and
potential for bias. We elected not to perform a meta-analysis
because inclusion was not limited based on study design and
therefore included both retrospective and prospective studies,
controlled and uncontrolled studies, and inpatient and outpatient
studies over more than a 40-year period. We elected this systematic review method as a way to include all relevant clinical data
rather than to signiﬁcantly truncate an already small data set. A
comparison to doxycycline was included if available; however,
this was not required because the investigators sought to identify
the potential utility of minocycline during doxycycline shortage
rather than an alternative to doxycycline under circumstances of
adequate supply. Therefore, our recommendations regarding the
use of minocycline are placed into this context, based upon the
data presented, developed in consideration of additional alternatives to doxycycline, and should be considered along with patientspeciﬁc factors, especially as they relate to potential ADRs.

therapy with minocycline 100 mg twice daily [20, 21], and the
third study continued minocycline 100 mg once daily [19].
Three studies dosed minocycline 100 mg twice daily without
a loading dose [23, 25, 26], 1 study dosed minocycline 100 mg
twice daily or 200 mg twice daily [22], and the ﬁnal study did not
report speciﬁc dosing [24]. Cure rate was high (89%) in the 7
studies that reported cure speciﬁc to minocycline use [19–24,
26]. However, in 1 report [26], 2 of 6 (33%) patients with severe
infection failed minocycline therapy. One patient was infected
with an organism resistant to minocycline, and the other patient suffered from concurrent bacteremia. In contrast, the largest single report of minocycline use in SSTIs demonstrated cure
in all 15 patients treated for severe Staphylococcus aureus infections [21]. Limitations of the data must be recognized. Only 4
studies were prospective, and none were randomized. The largest single report of minocycline use in SSTIs included only 15
patients. In addition, reports were generally limited in their description of nonpharmacologic treatments or in details regarding infection purulence. Therefore, the potential exists that
some patients included in these reports may be treated differently based on current guidelines, that is, incision and drainage
without systemic antibiotics. However, it should be noted that
several of the studies did include patients with severe or complicated infections that would most likely require systemic antibiotics under current guidelines [19, 21, 22, 26].

•
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Study/Sample Size

Design/ Setting

Population/Condition/Age;
Mean or Median (Range), Years

Reported
Treatment(s)

Outcome(s)
N (%)

Potential for Bias

Skin and soft tissue infections
Cappel and
Klastersky [19]
N = 20

Retrospective/inpatient/
Belgium

Disseminated malignancy
moderately severe (investigator
reported) bacterial infection
Age: 63 (25–77)
SSTI, N = 11

Minocycline (route not reported)
DOT: 7 d

Phair et al [20]
N = 10

Prospective uncontrolled/
outpatient/United States

Purulent SSTI, identified
Staphylococcus aureus
Age: not reported

Minocycline (PO)
Cure:
DOT: 8–18 d
8/10 (80)
Local soaks and debridement PRN

Raff et al [21]
N = 15

Prospective uncontrolled/
not reported/United
States

Severe (investigator reported) S aureus Minocycline (PO)
SSTIs
DOT: 6–28 d
Age: 56 (22–83)

Cure:
15/15 (100)

Uncontrolled study
Small sample size
Limited description of
nonpharmacologic intervention

Clumeck et al [22]
N = 25

Prospective uncontrolled/
inpatient/Belgium

Severe S aureus infection;
Age: 62 (18–88)
SSTI, N = 4
Other cohort indications: PNA,
osteomyelitis septic
thrombophlebitis, febrile urinary tract
infection, endocarditis, and liver
abscess

SSTI Cure:
3/4 (75)

Uncontrolled study; small sample size
Limited description of
nonpharmacologic intervention
21 patients received minocycline 100
mg Q12H, and 4 patients received
200 mg every Q12H

Ruhe et al [23]
N = 24

Retrospective/inpatient/
United States

Serious, tetracycline-susceptible MRSA
infection
Minocycline (PO); N = 5
Age: 51 (28–94)
Doxycycline (PO); N = 11
Complicated SSTI, N = 16

Cure:
5/5 (100)
10/11 (91)

Retrospective; small sample size
Allowed alternative initial antibiotic if
≤50% of appropriate treatment
duration
DOT not reported specific to SSTI

Barnes et al [24]
N = 30

Retrospective review with Nonserious; MRSA-SSTI; cellulitis,
prospective observation/
abscess, or both
outpatient/United States Age: 46 (18–83)

Cure:
3/3 (100)
1/1 (100)
6/6 (100)
8/8 (100)
4/4 (100)
5/5 (100)
3/3 (100)

Retrospective/observational; small
sample size
Dosing not reported; DOT not
reported
1 patient treated with drainage only,
and 1 patient treated with βlactam + drainage experience
recurrence after 30 d

Cure:
86/90 (96)
168/192 (88)

Retrospective
Few patients received minocycline
Clinical outcomes of minocycline/
doxycycline reported as aggregate
20 of 168 β-lactam treatment
successes occurred in patients
changed from
β-lactam to targeted therapy based on
antimicrobial susceptibility data

Ruhe and Menon [25] Retrospective/ outpatient/
N = 282
United States

Minocycline + rifampin
Entire cohort (N = 25) description
DOT: 5–119 d
(mean 22)
(PO, N = 20; IV, N = 5)

Minocycline (PO)
Doxycycline (PO)
Trim/sulfa (PO)
Clindamycin (PO)
Drainage only
β-lactam (PO) + drainage
Fluoroquinolone (PO)

Community-acquired purulent S aureus Minocycline (PO); N = 3 or
SSTI
Doxycycline (PO); N = 87
Age: 48 (18–85)
DOT: 3–20 d
(median 10)
Incision/drainage; 77%
β-lactam (PO and/or IV); N = 192
DOT: not reported
Incision/drainage; 81%

Cure:
10/11 (91)

Retrospective; small sample size
Minocycline dose lower than current
standard
Compromised patient population
Uncontrolled study
Small sample size
Limited description of
nonpharmacologic intervention
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Study/Sample Size
Rogers et al [26]
N = 24

Design/ Setting
Prospective uncontrolled/
inpatient/United States

Population/Condition/Age;
Mean or Median (Range), Years

Reported
Treatment(s)

Severe (investigator reported) infections Minocycline (IV)
SSTI, N = 6
Age: 56 (43–77)
Mixed PNA, N = 14
Age: 48 (5–84)

Outcome(s)
N (%)
Cure:
SSTI; 4/6 (67)
Mixed PNA;
14/14 (100)

Potential for Bias
Uncontrolled, small sample size
Heterogeneous disease states
DOT: Not reported

Community-acquired pneumonia
Kawai et al [27]
N = 30

Prospective uncontrolled/
inpatient or outpatient/
Japan

Mycoplasma pneumoniae CAP
Macrolide resistant, N = 21
Age: 8 (1–15)

Minocycline required for 15 patients Defervesce within
with macrolide treatment failure 48 H:
DOT: 8–11 d
15/15 (100)
(route not reported)

Uncontrolled study; only included
confirmed M pneumonia; small
sample size
Clinical outcome assessed as
presence of fever
Minocycline used as secondary agent

Okada et al [28]
N = 202

Prospective observational/
inpatient or outpatient/
Japan

M pneumoniae CAP
Macrolide resistant, N = 176
Age: 8 (1–14)

Secondary agent used in macrolide
resistance:
Minocycline; N = 52
DOT: 2–7 d (mean 5)
Doxycycline; N = 16
DOT: 3–7 d (mean 3)
Macrolides; N = 13
DOT: 3–10 d (mean 6)
Tosufloxacin; N = 13
DOT: 2–7 d (mean 5)
(routes not reported)

Defervesce within 48 H: Observational study; only included
confirmed M pneumoniae
47 (90)
Clinical outcome assessed as
presence of fever
14 (88)
Minocycline used as secondary agent
6 (46)
9 (69)

Systematic Review of Minocycline

Kawai et al [29]
N = 188

Prospective observational/
inpatient or outpatient/
Japan

M pneumoniae CAP
macrolide resistant, N = 150
Age: 8 (0–15)

Definitive treatment in macrolide
resistance:
Minocycline, N = 38
Azithromycin, N = 27
Clarithromycin, N = 23
Tosufloxacin, N = 62
(routes not reported)

Defervesce within 48 H: Observational study; only included
confirmed M pneumoniae
33 (87)
Clinical outcome assessed as
11 (41)
presence of fever
11 (48)
Minocycline (age ≥8)/tosufloxacin
43 (69)
(age <8) used as definitive therapy
Treatments determined by attending
physician/not standardized
DOT: Not reported

Miyashita et al [30]
N = 73

Prospective observational/
inpatient or outpatient/
Japan

M pneumoniae CAP Macrolide
resistant, N = 30
Age: 23 (16–45)

Initial treatment in macrolide
resistance:
Minocycline, N = 7
Macrolides, N = 14
Quinolones, N = 9
(All admitted patients received IV
minocycline, other specifics of
route not reported)

Defervesce within 48 H: Observational study; only included
confirmed M pneumoniae; small
6 (85)
sample size
4 (28)
Clinical outcome assessed as
7 (77)
presence of fever
DOT: Not reported
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Lyme disease
Weber et al [31]
N = 107

Design/ Setting

Population/Condition/Age;
Mean or Median (Range), Years

Prospective,
Early erythema migrans, N = 97
nonrandomized
Age: Not adequately reported
intervention/not reported/
Germany

Reported
Treatment(s)

Minocycline, N = 11
DOT: 10–15 d
Doxy/tetracycline, N = 8
DOT: 10–14 d
Penicillin (PO), N = 65
DOT: 10–14 d
Penicillin (parenteral), N = 7
DOT: 10–14 d
Erythromycin, N = 6
DOT: 10 d
(other routes not specifically
reported)

Outcome(s)
N (%)
Time to cure (weeks):
mean/median
7/2

Potential for Bias
Nonrandomized; small sample size
Limited differentiation in outcomes
between minocycline and
doxycycline

19/2
22/2
7/2
2/9

Muellegger et al [32]
N = 14

Prospective uncontrolled/
not reported/Austria

Erythema migrans, Borrelia
burgdorferi DNA confirmed (57%)
Age: 53 (34–79)

Minocycline (PO); N = 14
DOT: 14 d

Good clinical response: Uncontrolled; small sample size
14/14 (100)

Breier et al [33]
N = 60

Prospective open label
randomized/outpatient/
Austria

Erythema migrans
Age: 43 (19–80)

Minocycline, N = 30
DOT: 21 d
Penicillin V, N = 30
DOT: 21 d
(route not reported)

Both groups:
Complete recovery; no
late disease at 1 y

Withdraw due to side effects
(minocycline, 12; penicillin V, 9)
excluded from analysis
Open label design; small sample size

Schmidt et al [34]
N = 26

Prospective uncontrolled/
not reported/Austria

Erythema migrans
Age: 56 (20–84)

Minocycline (PO)
DOT: 14 d

8 wks post therapy:
20/22 (91) Erythema
Migrans clear; 0/22
(0) Additional
symptoms present

Uncontrolled; small sample size
4 patients lost to follow up at 8 wks
Limited report of clinical outcomes

Stanek et al [35]
N = 99

Prospective uncontrolled/
outpatient/Austria

Erythema migrans
Age: 50 (10–80)

Minocycline (PO)
Amoxicillin (PO)
Azithromycin (PO)
Doxycycline (PO)
Penicillin V (PO)
DOT: 2–3 wks (all treatments)

Complete resolution in
all patients within 3
wks

Uncontrolled; limited report of clinical
outcomes
Number of patients treated with each
antibiotic not reported

Minocycline (PO), N = 61*
Doxycycline (PO), N = 13*
β-lactam (PO/IV), N = 36
DOT: Not reported

Complete symptom
resolution within 1
mo:
109/113 (96)

Retrospective; variable antibiotic
treatment
Limited report of clinical outcomes
Clinical outcome reported as
aggregate

Cure:
25/25 (100%)
2/2 (100%)

Retrospective, small sample size
Minocycline dosing not reported
DOT: Not reported

Glatz et al [36]
N = 113

Retrospective/not reported/ Erythema migrans
Austria
Age: 51 (5–78)

Rickettsial infections
Kodama et al [37]
N = 28

Retrospective/inpatient/
Japan

Japanese spotted fever
Age: 60 (12–78)
Died before treatment, N = 1

Minocycline; N = 25
Minocycline + steroids; N = 2
(route not reported)

Abbreviations: CAP, community-acquired pneumonia; DOT, duration of therapy; H, hours; IV, intravenous; MRSA, methicillin-resistant S aureus; PNA, pneumonia; PO, per oral; PRN, as needed; Q, every; SSTI, skin and softtissue infections; Trim/sulfa, trimethoprim/sulfamethoxazole.
a

Values calculated from data presented in Table 1 of Arch Dermatol 2006;142(7):862–868.
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Flow diagram of study selection.

erythema migrans [31–36]. Each study—including 1 prospective open-label randomized study—demonstrated high cure
rates with minocycline therapy. In the randomized study,
minocycline was compared with penicillin V. The dropout
rate was high, with 30% ( penicillin V) and 40% (minocycline)
of patients stopping treatment before completing the planned
21-day course [33]. All patients that completed the course of
minocycline achieved cure at the end of therapy and were symptom free at 1 year. In the most recent report, 109 of 113 (96.5%)
patients treated for early erythema migrans with minocycline,
doxycycline, or a β-lactam achieved complete symptom resolution by 1 month [36]. However, this report was primarily focused upon serum antibody responses and did not report
cure per treatment strategy. However, >50% of the patients
were treated with minocycline, and only 4 patients overall had
any remaining symptoms at 1 month.
Rickettsial Disease

The 1 identiﬁed report regarding rickettsial disease was in 28
Japanese patients treated for Japanese spotted fever, the causative organism being Rickettsia japonica [37]. Twenty-seven
(96%) patients achieved cure with minocycline therapy. One patient with fulminant disease died before administration of

minocycline. The study included 5 other patients with severe
and potentially life-threatening diseases that were successfully
treated with minocycline.
DISCUSSION
Skin and Soft-Tissue Infection

The data reported herein support the effectiveness of minocycline in a broad range of SSTIs. Patients that are immunocompromised or presenting with severe disease will likely be treated
with nontetracycline intravenous antibiotics, in line with the
current standard of care [17, 26, 62]. However, in circumstances
amenable to the use of doxycycline, it appears that minocycline
is more than a reasonable alternative. In addition, there are no
pharmacokinetic properties, in vitro data, or in vivo data that we
are aware of that portend minocycline to be inferior to doxycycline in the treatment of SSTIs. The 2011 Infectious Disease Society of America (IDSA) MRSA (methicillin-resistant S aureus)
guideline [17] includes “doxycycline or minocycline” as A-II
treatment options for empirical coverage of communityacquired MRSA SSTIs in outpatients. Furthermore, minocycline
may be advantageous over doxycycline because it does not appear to be prone to inducing its own resistance [63]. These ﬁnal
Systematic Review of Minocycline
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Figure 2.

points are absent from the most recent SSTI guidelines from the
IDSA [62], potentially omitted to aid concision because the
MRSA guidelines are still considered up-to-date. Therefore,
we recommend minocycline substitution for doxycycline in
the treatment of SSTIs during doxycycline shortage. Considering the frequency of SSTIs [62], the substitution of minocycline
is a reasonable initiative to conserve doxycycline supplies for indications with less desirable alternatives.

The decision to use minocycline in CAP must be considered in
context of the overarching treatment recommendations for CAP
[18, 64–66]. Current guidelines recommend doxycycline monotherapy as an alternative treatment only for otherwise healthy
patients with low risk for drug-resistant Streptococcus pneumoniae (weak recommendation, level III evidence) [18]. Likewise,
we found limited evidence to support minocycline monotherapy in severe infections or in conﬁrmed S pneumoniae infection. The reviewed data for minocycline in CAP were positive
but mostly limited to M pneumoniae infection. In considering
the outpatient treatment of young otherwise healthy patients—
where atypical organisms ( primarily M pneumoniae) may be of
more concern—minocycline could be used within the same
framework in which doxycycline is recommended. Our recommendation also takes into consideration the increased vaccination for pneumococcus and the typically severe presentation of
Legionnaires’ disease [66]. Overall, empirical tetracycline
monotherapy should be reserved for uncomplicated cases of
CAP [18].
Contrary to this narrow recommendation, there is compelling data to support minocycline’s use in CAP speciﬁcally
caused by macrolide-resistant M pneumoniae [27–30]. Considering the increased incidence of macrolide-resistance M pneumoniae in the United States and globally [67], there will likely
be an increased need for tetracycline therapy in CAP. Furthermore, there is increased attention to the cardiovascular risk proﬁle of macrolides and ﬂuoroquinolones, both of which are
commonly used for empirical coverage of atypical pathogens
in CAP [68, 69]. For patients with underlying cardiac comorbidities, tetracyclines, including minocycline, may be preferred as
adjuncts to antipneumococcal β-lactams. In circumstances in
which there is concern for treating macrolide-resistant M pneumoniae or when doxycycline would be preferred for empirical
atypical coverage, we recommend substituting minocycline for
doxycycline.
Lyme Disease Prophylaxis

At this time, the CDC only recommends doxycycline as an option for Lyme disease prophylaxis due to lack of evidence with
other medications. The CDC speciﬁcally recommends against
single-dose amoxicillin due to its short half-life (eg, approximately 1 hour) [1, 70]. However, minocycline has an extended
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Rickettsial Diseases

The literature to support the use of minocycline in rickettsial
diseases is severely limited. Although the included report of Japanese spotted fever had a rate of life-threatening disease on par
with Rocky Mountain spotted fever—the most common rickettsial disease in the United States—it is difﬁcult to use these data
as a surrogate. Rocky Mountain spotted fever is a circumstance
that warrants retaining a supply of doxycycline in endemic
areas. However, the CDC did not deﬁnitively recommend alternative therapy should doxycycline be entirely unavailable [1].
Therefore, we pose that it is worthy to consider minocycline’s
place in therapy for Rocky Mountain spotted fever—given its lethality—in the scenario of complete doxycycline unavailability.
Older and in vitro data demonstrate that tetracycline may be
a potential alternative to doxycycline [78–80]. To our knowledge, there are no reports of increasing resistance of Rickettsia
rickettsii to any tetracycline antibiotic. Considering minocycline
and doxycycline’s similar pharmacokinetic and susceptibility
proﬁles, we portend minocycline to be a potential alternative,
despite the dearth of clinical data. Important in this consideration is that further alternatives may be considerably less desirable. The CDC mentions the potential use of chloramphenicol
as an alternative to doxycycline [1]. However, the CDC rightly
notes that chloramphenicol is associated with a greater mortality risk compared with treatment regimens that include a tetracycline. This fact is supported by 2 large surveillance studies
that demonstrate chloramphenicol monotherapy to be statistically associated with fatal disease compared with treatment
with any tetracycline as monotherapy or with any tetracycline
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half-life similar to doxycycline (eg, >12 hours) [7, 9]. Minocycline appears effective in the treatment of early Lyme disease
[31–36]. Unfortunately, we found no data regarding minocycline for Lyme disease prophylaxis following tick bite. However,
most studies regarding prophylaxis are equivocal due to the low
event rate [71–75]. The most recent guideline from the IDSA
includes an option for prophylaxis with single-dose doxycycline
in patients meeting strict criteria [76]. Therefore, when prophylaxis is indicated in the absence of doxycycline, we recommend
clinicians consider minocycline and exercise shared decision
making [77]. We recommend that this conversation include at
least 5 key points: (1) the overall risk of developing Lyme disease
is low and forgoing prophylaxis may be reasonable; (2) there are
effective treatments for early Lyme disease; (3) the beneﬁt of antibiotic prophylaxis is small and may be offset by the risk for
adverse effects with antibiotic treatment; (4) doxycycline is usually recommended, however, if unavailable, minocycline is a
similar but less studied antibiotic; and (5) although minocycline
may work better, as well, or not as well other antibiotics, it is
suggested as a potential alternative because it works similarly
to doxycycline, and it has been shown to be effective in patients
who have developed Lyme disease.

CONCLUSIONS
In conclusion, drug shortages interfere with the management of
infectious diseases and necessitate the use of less familiar alternatives. This systematic review supports the use of minocycline
as a substitute for doxycycline in SSTIs, an alternative in the
outpatient treatment of CAP in young otherwise healthy
patients (with more evidence in macrolide-resistant M pneumoniae), an alternative to doxycycline for Lyme disease prophylaxis (should prophylaxis be strongly desired and doxycycline is
unavailable), and a last alternative in select rickettsial diseases
should doxycycline be entirely unavailable. Given the myriad
of indications for which doxycycline can be used, further research, review, and guidance are needed to prepare practitioners, institutions, and health systems to provide adequate care in
the face of tetracycline shortages and antibiotic shortages in
general.
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